I’m ok with that. There are plenty of good biotechs who have people who can develop a great opportunity but they seem to wither a dry up as the cost of trials and ultimate commercialisation takes its toll. They are built for that stuff whereas the big boys do it everyday and have a massive machine churning out products.
our team need to figure out when to let go and how to license it so they not just get some big returns today as part of a transaction but also share in the ongoing revenue stream from such a great drug.
Picked up my first lot of NYR at 29c and topped up a bit more today at 33c but fear there is no big hurry as SP seems immune to good news. I am in no hurry and will pop these in the bottom drawer but I do wonder, what will be the trigger point for a rerate?
bull case, page-111
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $12.91M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 7.3¢ | 7.2¢ | $43.76K | 603.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85773 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 108705 | 2 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
0.002 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.3¢ | 7.1¢ | 239146 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| NYR (ASX) Chart |